Perfluorohexyloctane

Aldeyra Therapeutics is advancing with reproxalap for dry eye disease, despite mixed phase 3 trial results. After FDA discussions, it plans a US approval filing. Reproxalap showed rapid symptom improvement but faces competition from existing and emerging treatments like NOV03.

Miebo and Xdemvy, FDA-approved dry eye disease treatments, have significantly impacted DED care, outperforming phase 3 trials with positive patient results and minimal side effects. Miebo, addressing evaporation, sold $162.6M in its first year, while Xdemvy, targeting Demodex blepharitis, achieved $126M in sales, both showing rapid symptom relief and improved patient outcomes.

Bausch + Lomb acquires Elios Vision, Inc., enhancing its glaucoma treatment portfolio with the ELIOS™ MIGS procedure, a clinically validated, implant-free surgery. The acquisition aims to address the rising glaucoma prevalence, leveraging Bausch + Lomb's global reach for widespread adoption. Despite strong financial performance, analysts express caution over stock valuation.

MIEBO is an ophthalmic solution for dry eye disease, administered 4 times daily. It was approved based on two clinical trials involving 1,217 patients. The trials showed MIEBO improved corneal surface and dryness symptom scores. Efficacy and side effects were consistent across sex, race, and age groups. Common side effects included blurred vision and headache.

Perfluorohexyloctane ophthalmic solution showed greater reductions in corneal fluorescein staining and eye dryness scores compared to a hypotonic saline control in patients with dry eye disease associated with Meibomian gland dysfunction, across various demographic and disease subgroups.

80% of glaucoma patients on prostaglandin analogs (PGAs) have Grade 2-3 meibomian gland dysfunction (MGD), worsening ocular surface disease (OSD). Benzalkonium chloride (BAK) in chronic drops disrupts tear film stability. Symptoms like redness and tearing can lead to poor medication compliance and glaucoma progression. Innovative non-preserved or non-BAK glaucoma medications, sustained-release drug delivery systems, and non-drug treatments like selective laser trabeculoplasty (SLT) or minimally invasive glaucoma surgeries (MIGS) offer solutions. Preservative-free drops and procedural interventions aim to mitigate MGD and OSD effects.